Skip to Content
Merck
CN
  • Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.

Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.

Cell reports (2022-02-03)
Mehmet Sahin, Melissa M Remy, Benedict Fallet, Rami Sommerstein, Marianna Florova, Anna Langner, Katja Klausz, Tobias Straub, Mario Kreutzfeldt, Ingrid Wagner, Cinzia T Schmidt, Pauline Malinge, Giovanni Magistrelli, Shozo Izui, Hanspeter Pircher, J Sjef Verbeek, Doron Merkler, Matthias Peipp, Daniel D Pinschewer
ABSTRACT

Across the animal kingdom, multivalency discriminates antibodies from all other immunoglobulin superfamily members. The evolutionary forces conserving multivalency above other structural hallmarks of antibodies remain, however, incompletely defined. Here, we engineer monovalent either Fc-competent or -deficient antibody formats to investigate mechanisms of protection of neutralizing antibodies (nAbs) and non-neutralizing antibodies (nnAbs) in virus-infected mice. Antibody bivalency enables the tethering of virions to the infected cell surface, inhibits the release of virions in cell culture, and suppresses viral loads in vivo independently of Fc gamma receptor (FcγR) interactions. In return, monovalent antibody formats either do not inhibit virion release and fail to protect in vivo or their protective efficacy is largely FcγR dependent. Protection in mice correlates with virus-release-inhibiting activity of nAb and nnAb rather than with their neutralizing capacity. These observations provide mechanistic insights into the evolutionary conservation of antibody bivalency and help refining correlates of nnAb protection for vaccine development.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pepsin from porcine gastric mucosa, lyophilized powder, ≥3,200 units/mg protein